Literature DB >> 16767476

[Lung cancer].

R M Huber1.   

Abstract

Although various benign and malignant tumors can occur in the bronchi and lungs, lung cancer is by far the most common tumor and the leading cause of tumor death worldwide. For therapeutic reasons lung cancer is classified currently as small cell (SCLC) or non small cell lung cancer (NSCLC). The main cause is smoking. There are no specific symptoms that enable early detection. Staging is according to the international TNM-system. As the results of therapy to date are disappointing and many questions remain unsolved, as many patients as possible should be included in further prospective trials. In SCLC polychemotherapy is mandatory; in local tumor stages radiotherapy should be combined early on with chemotherapy, and in cases of complete remission, prophylactic cranial irradiation is indicated. In operable stages of NSCLC adjuvant chemotherapy demonstrates a survival benefit. In locally advanced NSCLC, radiochemotherapy is now the standard of care. Advanced stages require chemotherapy usually with two drugs, second-line chemotherapy is indicated in cases of relapse.

Entities:  

Mesh:

Year:  2006        PMID: 16767476     DOI: 10.1007/s00108-006-1581-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  9 in total

1.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

Authors:  K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

2.  [Recommendations for bronchoscopic treatment of tracheobronchial occlusions, stenoses and mural malignant tumors. German Society of Pneumology "Quality Assurance in Bronchology" Working Group].

Authors: 
Journal:  Pneumologie       Date:  1998-05

3.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

Review 5.  Functional evaluation of the lung resection candidate.

Authors:  C T Bolliger; A P Perruchoud
Journal:  Eur Respir J       Date:  1998-01       Impact factor: 16.671

6.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

7.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

Authors:  K S Albain; J J Crowley; M LeBlanc; R B Livingston
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

8.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

9.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.